Adults

60 mg orally once daily with food, for 8-24 weeks, or as determined by the prescribing physician based on HCV genotype and specific treatment regimen.

Elderly

No specific dose adjustment is required for elderly patients; however, monitor for age-related decline in renal or hepatic function.

Renal_impairment

No dose adjustment is necessary for mild to moderate renal impairment (eGFR ≥30 mL/min). Use with caution and monitor closely in severe renal impairment (eGFR <30 mL/min) or end-stage renal disease (ESRD).

Onset

Antiviral effects are generally observed within hours to days of initiation of therapy, with significant reductions in viral load noted within the first week.

Excretion

Mainly excreted via feces (approximately 80%), with a smaller portion (approximately 15%) eliminated via urine.

Half life

The elimination half-life is approximately 12-15 hours, supporting once-daily dosing.

Absorption

Rapidly absorbed after oral administration, with peak plasma concentrations typically achieved within 2-4 hours. Bioavailability is enhanced when taken with food.

Metabolism

Primarily metabolized in the liver, likely via cytochrome P450 enzymes (e.g., CYP3A4) and/or other non-CYP pathways.

Amiodarone

Co-administration with certain DAAs has been associated with symptomatic bradycardia. Use with caution; monitor heart rate and advise patients about symptoms of bradycardia.

Proton Pump Inhibitors (PPIs) and H2-receptor Antagonists

May alter Dasvir absorption. Consult prescribing information for specific guidance on co-administration.

Strong CYP3A4 Inducers (e.g., Rifampin, Carbamazepine, Phenytoin, St. John's Wort)

May significantly decrease Dasvir plasma concentrations, leading to reduced therapeutic effect and potential treatment failure. Concomitant use is contraindicated.